Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
6857.5 EUR
In Stock
quantity
Produktdetaljer
Katalognummer: 421 - 78737-2
Produktkategori: Företag och industri > Vetenskap och laboratorium
Gentaur
Storlek: 500 µl x 2
Parameters
| Additional information | Applications: Screen for neutralizing antibodies against the SARS-CoV-2 XBB.1.5 variant in ACE2-HEK293 cells; |
|---|---|
| Storage and shipping | Shipping conditions: -80°C; Storage conditions: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the virus at -80°C.; |
| Storage and shipping | With |
78737-1
Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of January 2023, additional new sub-lineages (e.g. BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5) have been designated._x000D_The Spike (XBB.1.5 Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron XBB.1.5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 XBB.1.5 variant in a Biosafety Level 2 facility._x000D_<p style="text-align: center;"><img src="{{media url="wysiwyg/coronavirus/78737.png"}}" alt="" width="451" height="352" />_x000D_Figure 1. Schematic of the eGFP Reporter in Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus._x000D_As shown in Figure 2 in Validation Data, the Spike Omicron XBB.1.5 pseudovirus has been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951)._x000D_Spike Mutations in XBB.1.5 Omicron Variant: T19I, LPP24-26del, A27S, V83A, G142D, Y144del, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
1462.5 €
78785-1
Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
The Spike (XBB.1.16 Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron XBB.1.16 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain eGFP driven by a CMV promoter (Figure 1), allowing the spike-mediated cell entry to be measured by the eGFP fluorescence signal. The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 XBB.1.16.The Spike Omicron XBB.1.16 pseudoviruses have been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951) .Figure 1. Schematic of the lenti-vector used to generate the eGFP Reporter in the Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus.
Ask for quotation
78785-2
Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
The Spike (XBB.1.16 Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron XBB.1.16 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain eGFP driven by a CMV promoter (Figure 1), allowing the spike-mediated cell entry to be measured by the eGFP fluorescence signal. The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 XBB.1.16.The Spike Omicron XBB.1.16 pseudoviruses have been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951) .Figure 1. Schematic of the lenti-vector used to generate the eGFP Reporter in the Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus.
Ask for quotation
78980-2
Spike (BA.2.86, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
The Spike (BA.2.86, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the BA.2.86 mutations; see below for details) as the envelope glycoprotein, instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase reporter driven by a CMV promoter (Figure 1), allowing to measure spike-mediated cell entry using luciferase activity.These pseudoviruses have been validated in a cellular assay with ACE2-HEK293 Recombinant Cell Line (#79951), a cell line that overexpresses ACE2 at high levels, as target cell line.Figure 1. Schematic of the lenti-vector used to introduce the luciferase reporter inSpike (BA.2.86, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) .
Ask for quotation
78981-1
Spike (JN.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
The Spike (JN.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the JN.1 mutations; see below for details) as the envelope glycoprotein, instead of the commonly used VSV-G. These pseudovirions also contain a firefly luciferase reporter driven by a CMV promoter (Figure 1), allowing to measure spike-mediated cell entry using luciferase activity.These pseudoviruses have been validated in a cellular assay with ACE2-HEK293 Recombinant Cell Line (#79951), a cell line that overexpresses ACE2 at high levels, as target cell line.Figure 1. Schematic of the lenti-vector used to introduce the luciferase reporter inSpike (JN.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) .
Ask for quotation
78981-2
Spike (JN.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
The Spike (JN.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the JN.1 mutations; see below for details) as the envelope glycoprotein, instead of the commonly used VSV-G. These pseudovirions also contain a firefly luciferase reporter driven by a CMV promoter (Figure 1), allowing to measure spike-mediated cell entry using luciferase activity.These pseudoviruses have been validated in a cellular assay with ACE2-HEK293 Recombinant Cell Line (#79951), a cell line that overexpresses ACE2 at high levels, as target cell line.Figure 1. Schematic of the lenti-vector used to introduce the luciferase reporter inSpike (JN.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) .
Ask for quotation
Håll dig uppdaterad! Visa tidigare publikationer
By: Author , 2 Comment
Katalas – ett extraordinärt enzym
30 January 2026
By: Author , 2 Comment
Anaplasmos hos hundar och katter – allt du behöver veta
23 August 2025
By: Author , 2 Comment
Solbränna – hur leker man säkert i solen?
16 August 2025
By: Author , 2 Comment
Biologiska läkemedel – Modernitet inom farmaci
1 August 2025